MANTOVANI, GIOVANNI
 Distribuzione geografica
Continente #
EU - Europa 33.958
NA - Nord America 3.851
AS - Asia 1.643
SA - Sud America 185
AF - Africa 30
OC - Oceania 1
Totale 39.668
Nazione #
IT - Italia 32.990
US - Stati Uniti d'America 3.774
CN - Cina 629
SG - Singapore 588
UA - Ucraina 275
SE - Svezia 200
BR - Brasile 142
VN - Vietnam 118
GB - Regno Unito 113
DE - Germania 104
FI - Finlandia 101
FR - Francia 86
HK - Hong Kong 73
KR - Corea 59
CA - Canada 55
IN - India 55
BD - Bangladesh 19
BE - Belgio 16
IQ - Iraq 15
ES - Italia 13
JP - Giappone 13
RU - Federazione Russa 13
AR - Argentina 11
ZA - Sudafrica 11
NL - Olanda 10
PK - Pakistan 10
TR - Turchia 10
MX - Messico 9
PH - Filippine 9
PL - Polonia 9
IR - Iran 8
CL - Cile 7
JM - Giamaica 6
CR - Costa Rica 5
EC - Ecuador 5
AT - Austria 4
CO - Colombia 4
LT - Lituania 4
MY - Malesia 4
PY - Paraguay 4
UZ - Uzbekistan 4
VE - Venezuela 4
AL - Albania 3
BO - Bolivia 3
CG - Congo 3
JO - Giordania 3
KE - Kenya 3
LV - Lettonia 3
PE - Perù 3
SA - Arabia Saudita 3
TN - Tunisia 3
AZ - Azerbaigian 2
DZ - Algeria 2
EG - Egitto 2
ID - Indonesia 2
IE - Irlanda 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NO - Norvegia 2
NP - Nepal 2
PS - Palestinian Territory 2
PT - Portogallo 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LY - Libia 1
MA - Marocco 1
MN - Mongolia 1
MU - Mauritius 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
RS - Serbia 1
TG - Togo 1
TH - Thailandia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 39.668
Città #
Cagliari 31.932
Uta 856
Fairfield 406
Ashburn 343
Singapore 320
Woodbridge 265
Chandler 230
San Jose 218
Houston 204
Seattle 191
Nyköping 179
Boardman 158
Wilmington 153
Jacksonville 152
Cambridge 151
Ann Arbor 149
Dallas 148
Beijing 114
Los Angeles 71
Dearborn 64
Hong Kong 63
Santa Clara 63
Shanghai 53
Helsinki 51
Ho Chi Minh City 51
Seoul 51
Boston 49
Nanjing 49
Lauterbourg 48
New York 44
Guangzhou 36
Hefei 34
Buffalo 31
London 28
Hanoi 24
Changsha 22
The Dalles 22
Toronto 22
Pune 21
San Diego 21
Shenyang 18
Brussels 16
Milan 15
Munich 15
Rome 15
Tianjin 15
Council Bluffs 13
Chicago 12
Nanchang 12
Jiaxing 11
Redondo Beach 11
Jinan 9
Montreal 9
Redwood City 9
Atlanta 8
Baghdad 8
Norwalk 8
Tokyo 8
Orange 7
San Mateo 7
São Paulo 7
Ankara 6
Auburn Hills 6
Belo Horizonte 6
Chennai 6
Hangzhou 6
Kunming 6
Orem 6
Phoenix 6
Turku 6
Verona 6
Warsaw 6
Barcelona 5
Brandizzo 5
Brooklyn 5
Denver 5
Hebei 5
Kingston 5
Poplar 5
Rio de Janeiro 5
San Francisco 5
Shenzhen 5
Stockholm 5
Wuhan 5
Augusta 4
Chongqing 4
Colombo 4
Curitiba 4
Detroit 4
Frankfurt am Main 4
Haiphong 4
Kilburn 4
Mountain View 4
Mumbai 4
Sassari 4
Somma Vesuviana 4
Torino 4
Valencia 4
Amman 3
Bến Tre 3
Totale 37.508
Nome #
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.584
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.200
Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches 2.059
Advances in pharmacologic strategies for cancer cachexia 1.904
Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia 1.789
The nutritional risk in oncology: a study of 1,453 cancer outpatients 1.733
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 1.514
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 971
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response 955
Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients 938
null 936
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial 918
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer 891
null 819
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 809
Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy 779
Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer 753
Current medications for cancer cachexia 740
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2 703
null 681
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy 629
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs 612
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes 583
Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma 555
Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate 529
null 529
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation 527
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 522
Efficacy, compliance and prognostic significance of a comprehensive geriatric assessment in the geriatric cancer patient = Efficacia, applicabilità e significato prognostico di una valutazione geriatrica multidimensionale nel paziente oncologico anziano 517
Role of proinflammatory cytokines and leptin in cancer-related anorexia/cachexia. Metabolic abnormalities and therapeutic approaches = Ruolo delle citochine infiammatorie e della leptina nell'anoressia/cachessia neoplastica. Aspetti metabolici e terapeutici 511
Medroxyprogesterone acetate reduces the In vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 510
Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients 505
Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect 504
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation 489
Medroxyprogesterone acetate and megestrol acetate reduce cisplatin-induced serotonin release from human peripheral blood mononuclear cells of cancer patients 484
Neo-adjuvant organ-preserving chemotherapy in the management of locally advanced oral cavity and oropharynx cancer: A tentative quantitative evaluation of organ preservation and clinical response 477
Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC 466
Relationships betxween Fas expression, activation molecule CD25, and functional activity of tumor-associated lymphomonocytes from neoplastic effusions 461
Tumor-associated lymphomonocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokynes 458
Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 457
Neo-adjuvant (primary) organ-preserving chemotherapy in the management of locally advanced laryngeal carcinoma: Larynx preservation and clinical response 429
Anorexia/Cachexia and oxidative stress in cancer patients = Anoressia/Cachessia e stress ossidativo nei pazienti con cancro 402
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG) 369
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 330
Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non-PHA-prestimulated cells in patients with cancer 329
Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies 288
[p55 and p75 subunits of the IL 2 receptor, membrane bound and soluble, in peripheral lymphocytes in patients with solid tumors] 252
Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1α, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies 177
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial 151
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin 150
Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy 150
Immunologic assessment determined by response to IL-2 and immunophenotyping of tumor-infiltrating lymphocytes, of invaded and non invaded lymph nodes and of peripheral blood lymphocytes from twenty-one patients with primary laryngeal cancer 136
Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients 136
Preovulatory human follicular fluid in vitro inhibits interleukin (IL)- 1α, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes 122
Study of peripheral blood lymphocyte subset distribution and IL-2 receptor (IL-2 R) p55-p75 subunit expression in patients with cancer of different sites 122
[The immunological assessment of a combined therapeutic approach (chemo- + radiotherapy +/- surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage] 115
Evidence that granulosa cells inhibit interleukin-1α and interleukin-2 production from follicular lymphomonocytes 85
Medical imaging: a segmentation algorithm 37
Totale 39.781
Categoria #
all - tutte 63.477
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.477


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021120 0 0 0 0 0 0 0 0 0 0 0 120
2021/20221.343 108 104 90 69 154 83 60 91 118 102 158 206
2022/20232.436 185 235 180 175 175 290 71 461 164 146 211 143
2023/20243.628 245 128 131 271 356 660 389 235 196 352 304 361
2024/20254.739 389 796 834 760 493 783 278 55 91 73 102 85
2025/20262.540 161 128 330 225 253 157 455 111 211 325 141 43
Totale 39.781